Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Glenmark Pharmaceuticals Ltd - 532296 - Certificate From Practicing Company Secretary Under Regulation 40(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 31St March, 2021

 Enclosed please find herewith the copy of the certificate issued by M/s. Savita Jyoti Associates, Company Secretaries under Regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Half Year ended 31st March, 2021. Please take the same on records.
19-04-2021

Glenmark Life Sciences Files IPO Papers With Sebi

 Glenmark Life Sciences IPO: The offer will comprise a fresh issue of up to Rs 1,160 crore and an offer for sale of up to 73,05,245 equity shares of Rs 2 each of Glenmark Life Sciences by...
18-04-2021

Glenmark Pharma arm files paperwork for IPO with market regulator

 Glenmark Pharmaceuticals on Saturday said its wholly-owned arm Glenmark Life Sciences has filed paperwork to go public
17-04-2021
Bigul

Glenmark Pharmaceuticals Ltd - 532296 - Proposed Initial Public Offering ('IPO') Of Glenmark Life Sciences Limited- Filing Of Draft Red Herring Prospectus

 We wish to inform you that Glenmark Life Sciences Limited, a wholly owned subsidiary of Glenmark Pharmaceuticals Limited, has today, i.e. on April 16, 2021, filed a draft red herring prospectus with the Securities and Exchange Board of India for an initial public offer, comprising of a fresh issue of up to ?11,600 million and an offer for sale of up to 7,305,245 equity shares of ?2 each of Glenmark Life Sciences Limited, by Glenmark Pharmaceuticals Limited ('Offer'). In connection with the aforementioned Offer, the board of directors of Glenmark Pharmaceuticals Limited, at its meeting held today, i.e. April 16, 2021, accorded its approval for the offer for sale of up to 7,305,245 equity shares of ?2, in the Offer. The IPO will be subject to market conditions, receipt of applicable approvals and other considerations.
17-04-2021
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement By Glenmark Pharmaceuticals Limited (The 'Company') Of The Settlement Of The Offer And Proposal In Respect Of U.S.$200,000,000 2.00 Per Cent. Resettable Onward Starting Equity-Linked Securities Due 2022 ('Bonds').

 With respect to the above subject, we have made an announcement to the Singapore Exchange Securities Trading Limited dated April 16, 2021. Please find enclosed herewith a copy of the same as Annexure A.
16-04-2021

Domestic growth trajectory to remain strong for Glenmark in near term

 Debt reduction key if the stock is to fetch higher valuation multiples
15-04-2021
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement By Glenmark Pharmaceuticals Limited (The 'Company') Of The Results Of The Proposal In Respect Of Its U.S.$200,000,000 2.00 Per Cent. Resettable Onward Starting Equity-Linked Securities Due 2022 ('Bonds')

 With respect to the above subject, we have made an announcement to the Singapore Exchange Securities Trading Limited dated April 12, 2021. Please find enclosed herewith a copy of the same as Annexure A. You are requested to take the same on record.
12-04-2021
Bigul

Glenmark Pharmaceuticals Ltd - 532296 - Shareholding for the Period Ended March 31, 2021

 Glenmark Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click here
10-04-2021

Here is a Bull Spread Strategy on Glenmark Pharma by HDFC Securities

 The stock price has already given bullish breakout from the downward slopping trendline adjoining the highs of 08-Dec-2020 and 12-Jan-2021
09-04-2021

Improved cash flows, debt reduction crucial for Glenmark's prospects

 Glenmark is focused on out-licensing deals, which would help fund R&D costs, and help improve profitability as well as reduce some debt
05-04-2021
Next Page
Close

Let's Open Free Demat Account